Regenxbio（NASDAQ:RGNX）报告季度每股亏损$(1.01)，优于分析师预期的$(1.15)，提高了12.17%。这一数字比去年同期每股亏损$(1.43)增长了29.37%。公司报告季度销售额为2121万美元，低于分析师预期的2375万美元，减少了10.69%。这一数字比去年同期的2221万美元减少了4.50%。

以上内容来自Benzinga Earnings专栏，原文如下：

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.15) by 12.17 percent. This is a 29.37 percent increase over losses of $(1.43) per share from the same period last year. The company reported quarterly sales of $21.21 million which missed the analyst consensus estimate of $23.75 million by 10.69 percent. This is a 4.50 percent decrease over sales of $22.21 million the same period last year.